Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after a second ChAdOx1 nCoV-19 dose
Katarzyna Krzywicka, Anita van de Munckhof, Julian Zimmermann, Felix J. Bode, Giovanni Frisullo, Theodoros Karapanayiotides, Bernd Pötzsch, Mayte Sánchez van Kammen, Mirjam R. Heldner, Marcel Arnold, Johanna A. Kremer Hovinga, José M. Ferro, Diana Aguiar de Sousa, Jonathan M. Coutinho
Abstract
Vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare but life-threatening complication of adenoviral vaccination against COVID-19, has been reported almost entirely following the first dose. Krzywicka and colleagues report on 124 patients with VITT in a multinational registry diagnosed after dose 2; no specific events were observed after dose 1. These patients had early presentation, and two of the patients died.
Topics & Concepts
MedicineComplicationThrombosisVaccinationImmune systemVenous thrombosisInternal medicineImmunologyGastroenterologySurgeryHeparin-Induced Thrombocytopenia and ThrombosisPlatelet Disorders and TreatmentsVenous Thromboembolism Diagnosis and Management